Related Experiment Video
Updated: Dec 16, 2025
Intra-iliac Artery Injection for Efficient and Selective Modeling of Microscopic Bone Metastasis
Published on: September 26, 2016
Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis
Hidemasa Katsumi1, Shugo Yamashita1, Masaki Morishita1
1Department of Biopharmaceutics, Kyoto Pharmaceutical University.
Abstract:
Bone metastases can cause high morbidity and mortality, often developing as they advance, especially in patients with prostate and breast cancers. Most drugs are rarely distributed to the bone and are hence pharmacologically ineffective in treating bone metastases. The development of drug targeting technologies is required for the efficient treatment of bone metastases. To date, numerous bone-targeting ligands, including tetracyclines, bisphosphonates, aspartic acid, and aptamers have been developed and used for bone-targeted delivery of anti-tumor drugs, peptide/protein drugs, nucleic acid drugs, and diagnostic imaging agents. The conjugates of drugs with bone-targeting ligands were first developed in the field of bone drug targeting systems; macromolecular carriers and nanoparticles modified with these bone-targeting ligands have also been developed. Additionally, antibodies to prostate-specific membrane antigen (PSMA) and human epidermal growth factor receptor 2 (HER2) are used in active targeting bone metastatic prostate cancer and breast cancer, respectively. Some conjugates using antibodies to PSMA and HER2 were developed and used in clinical trials. In this review, recent challenges in the development of bone-targeted delivery systems and strategies for the treatment of bone metastasis have been summarized. Future development of novel drug formulations in order to optimize targeted drug delivery in the treatment of bone metastasis have also been discussed.
Insights
Targeting bone metastases, particularly from prostate and breast cancers, requires advanced drug delivery systems. Novel strategies and formulations are crucial for effective treatment of bone metastases.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Bone metastases significantly increase morbidity and mortality in advanced cancers, especially prostate and breast cancers.
- Conventional drugs show poor distribution to bone, limiting their efficacy against bone metastases.
- Efficient treatment necessitates the development of specialized drug targeting technologies for bone.
Purpose of the Study:
- To review recent advancements in bone-targeted delivery systems for treating bone metastases.
- To summarize current challenges and strategies in developing effective bone metastasis therapies.
- To discuss future directions in novel drug formulations for optimized targeted delivery.
Main Methods:
- Review of existing literature on bone-targeting ligands and drug delivery systems.
- Analysis of strategies employing ligands like tetracyclines, bisphosphonates, aspartic acid, and aptamers.
- Examination of antibody-based targeting strategies for prostate-specific membrane antigen (PSMA) and HER2.
Main Results:
- Development of bone-targeting ligands for delivering various agents, including anti-tumor drugs and diagnostic agents.
- Conjugates of drugs with ligands, macromolecular carriers, and nanoparticles have been engineered.
- Antibody-based conjugates targeting PSMA and HER2 have shown promise and entered clinical trials.
Conclusions:
- Bone-targeted delivery systems are essential for overcoming drug distribution limitations in treating bone metastases.
- Continued innovation in ligand design and formulation is key to improving therapeutic outcomes.
- Future research should focus on novel drug formulations to optimize targeted delivery and enhance treatment efficacy.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:21Drug Distribution: Tissue Binding
For...